Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-B7-H3 ADC
- Development stage
- Preclinical
- Lead developer
- Peking University First Hospital
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
177Lu-B7-H3 ADC is a preclinical radiolabeled antibody-drug conjugate (ADC) developed by Peking University First Hospital for the treatment of B7-H3-expressing tumors, particularly prostate cancer. The agent consists of a human monoclonal antibody targeting B7-H3 (CD276) conjugated to a topoisomerase inhibitor payload, which is further radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). By combining the targeted cytotoxic mechanism of the ADC with the localized radiation of radioligand therapy, 177Lu-B7-H3 ADC achieves synergistic antitumor efficacy. Preclinical studies in prostate cancer xenograft models have demonstrated significant tumor growth inhibition and survival benefits with manageable and reversible hematological toxicity.
- Other names
- 177Lu-B7-H3-ADC177Lu-labeled B7-H3 antibody-drug conjugate[177Lu]Lu-B7-H3 ADC
02
Targets
B7-H3
Beyond the preview
Go deeper on 177Lu-B7-H3 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-B7-H3 ADC.